Budapest Retina Associates Kft.

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Macular degeneration15 trials
• Diabetic eye disease9 trials

Phase

• Phase 312 trials
• Phase 26 trials
• Phase 2/34 trials
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Recruiting8 trials
• Completed5 trials
• Not yet recruiting2 trials

Lead sponsor

• AbbVie3 trials
• Boehringer Ingelheim2 trials
• Eyebiotech Limited2 trials
• 4d Molecular Therapeutics Inc.1 trial
• Alexion Pharmaceuticals Inc.1 trial
• and 14 more

Running trials

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

  NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

  NCT07614776· Phase 3· Amgen· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  2025-523938-10-00· Phase 3· Eyepoint Inc.· Source

• Recruiting

  Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)

  2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Annexon, Inc.· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  NCT05407636· Phase 3· AbbVie· Source

• Enrolling by invitation

  Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

  NCT03999801· Phase 2· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration7 recruiting
• Diabetic eye disease3 recruiting

Closed trials

• Completed

  A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

  NCT06591598· Phase 4· Bayer· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Completed

  A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT05019521· Phase 2· Alexion Pharmaceuticals Inc.· Source

• Completed

  A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

  NCT05066997· Phase 2/3· Oculis· Source

• Completed

  A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration

  NCT04757610· Phase 3· Opthea Limited· Source